Recent Articles in Top Stories

JHL Biotech, a Taiwan-China biotech, signed a $257 million partnership giving Sanofi rights to market a JHL rituximab biosimilar with China the first market; BioAtla of San Diego and Beijing will receive $100 million from Sinobioway for China rights to four BioAtla drug candidates; Aier Eye Hospital Group of Changsha will pay $84 million to buy out its partners in nine hospitals; Mandarin Capital Partners of China paid $17.4 million to acquire a majority stake in an Italian CMO, Mipharm SpA; GrandOmics, a Beijing third-generation sequencing company, raised $14 million in an A funding round; Beijing's BeiGene will collaborate with Cancer Genetics of New Jersey, a precision medicine company; Qiming Venture Partners led a Series B funding in MicroTech Medical, a Hangzhou diabetes device company; Mederi Therapeutics of Connecticut received CFDA approval for its non-surgical GERD treatment device; and AstraZeneca announced positive results from a Phase III trial of Tagrisso in patients with relapsed non-small cell lung cancer, including a China cohort. More details....

Stock Symbols: (TWO: 6540) (NYSE: SNY) (SHZ: 300015) (NSDQ: BGNE) (NSDQ: CGIX) (NYSE: AZN)

Share this with colleagues:  

Suzhou's Innovent Biologics raised $260 million in a Series D round to develop its portfolio of biologic drugs, a record venture funding for a China biopharma company; Luye Pharma completed its $269 million acquisition of Acino's transdermal drug delivery business; Novogene of Beijing, a sequencing company, closed a $75 million Series B round; dMed Company, a Shanghai CRO specialist, raised $8 million in a first-round financing; Uni-Bio Science of Hong Kong and Beijing Sun-Novo Pharma will co-develop multiple oral small molecule treatments for diabetes; WI Harper Group agreed to partner with two other investment firms to fund startups that have US-China cross-border promise; Germany's Boehringer Ingelheim announced a joint research project to treat hearing loss with China Southeast University; eimageglobal, a US-China company with an online China healthcare platform, will incorporate eUnity, a clinical image viewing product into the platform; Suzhou Alphamab and 3D Medicines (Sichuan) received approval from the US FDA to begin clinical trials of a PD-L1 bi-specific immunotherapy; Cellular Biomedicine of Shanghai and the Bay Area started a China Phase I clinical trial of its CAR-T immunotherapy; and MicuRx Pharma, a US-China anti-infectives company, began a US Phase I trial to test oral formulations of its novel antimicrobial. More details....

Stock Symbols: (HK: 2186) (HK: 690) (NSDQ: CBMG)

Share this with colleagues: